CONNECT WITH US
HealthTech

HealthTech

Herpes 'remedies' sold on Amazon and Walmart pose public health risk, FDA warns

Medical Xpress logo

Published on

Add as a preferred source on Google
Herpes 'remedies' sold on Amazon and Walmart pose public health risk, FDA warns

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them has been approved to treat the infection.

The U.S. Food and Drug Administration (FDA) has sent warning letters to Amazon and Walmart over herpes products sold on their websites. The agency said the items are unapproved drugs that can't legally be shipped across state lines.

"Effective treatment requires diagnosis and supervision by a licensed health care professional," the FDA wrote in both letters, dated Oct. 1.

Agency staff bought the products from the two sites in July. Outside sellers listed them, but Amazon and Walmart stored and shipped the orders through their own fulfillment programs, the FDA explained.

The Amazon letter names nine products: FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula and Genital Herpes Intimate Wash.

The Walmart letter cites three of the same items: HClear for him, Herstat GST and Terragen HG Formula.

Labels on the products claimed to fight outbreaks, cut down on repeat flare-ups, soothe sores and even fight viruses.

Several are sold as homeopathic, meaning they're made with heavily diluted ingredients. The FDA noted that homeopathic products face the same approval rules as any other drug.

The bigger concern is what happens when people rely on these products instead of seeing a doctor.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.